• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24014 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegunigalsidase alfa (Fabry disease) – Addendum to Project A23-95]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Uptake of mental health benefits in before and during the perinatal period: an analysis of Austrian health insurance data
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: dosing of a new generation anti-seizure panel by LC-MS/MS]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94]
2024     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Organisational structures of Canadian knowledge transfer or mobilization groups serving research in university hospitals and health technology assessment]
2024     Haute Autorite de sante (HAS) [Assessment of the endoscopic transluminal necrosectomy procedure in the treatment of acute necrotizing pancreatitis]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Optimal observation period after an electrical cardioversion under sedation]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for hip joint replacement]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Qualitative study on information needs and preferences of decision-makers regarding RedETS products]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V]
2024     Health Technology Wales (HTW) Liposuction for the treatment of chronic lymphoedema
2024     NIHR Health and Social Care Delivery Program Harnessing the power of language to enhance patient experience of the NHS complaint journey in Northern Ireland: a mixed-methods study
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Umbilical cord clamping at one minute, allowing stem cell harvesting, compared with delayed cord clamping - infant and maternal outcomes
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2024     Haute Autorite de sante (HAS) [Next generation sequencing gene panel for medical lung cancer care]
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of emergency departments with or without a co-located primary care driven urgent care center
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health and Social Care Delivery Program Current experience and future potential of facilitating access to digital NHS primary care services in England: the Di-Facto mixed-methods study
2024     Health Information and Quality Authority (HIQA) A summary of publicly-funded services for fertility preservation for medical reasons in selected countries
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dalbavancin (acute bacterial skin and skin structure infections) – Addendum to Project A23-19]
2024     NIHR Health and Social Care Delivery Program Integrating palliative care and heart failure: the PalliatHeartSynthesis realist synthesis
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Price and cost development of orphan drugs]
2024     NIHR Health and Social Care Delivery Program Types and aspects of support that young carers need and value, and barriers and enablers to access: the REBIAS-YC qualitative study
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of finerenone (Kerendia)]
2024     NIHR Health and Social Care Delivery Program Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: gene panel for the identification of inborn errors of immunity - evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT3 phosphorylation status by flow cytometry]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86]
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of molnupiravir (Lagevrio)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: description of specialized geriatric services and their organizational and clinical components in Canada (outside Quebec) and internationally]
2024     NIHR Health Technology Assessment programme Interventions for people with perceptual disorders after stroke: the PIONEER scoping review, Cochrane systematic review and priority setting project
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT5 phosphorylation status by flow cytometry]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92]
2024     NIHR Health and Social Care Delivery Program National stakeholder consultation on how to measure care home residents’ quality of life
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards : systemic treatment algorithm for metastatic or advanced colorectal cancer, palliative intent]
2024     NIHR Health Technology Assessment programme Timing of Stoma Closure in Neonates: the ToSCiN mixed-methods study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: confirmed chlamydia trachomatis or neisseria gonorrhoeae infection]
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Addendum to Commission A23-88]
2024     Health Information and Quality Authority (HIQA) Review of national rare disease strategies in selected countries
2024     NIHR Health and Social Care Delivery Program Investigating innovations in outpatient services: a mixed-methods rapid evaluation
2024     NIHR Health Technology Assessment programme Behavioural interventions to treat anxiety in adults with autism and moderate to severe intellectual disabilities: the BEAMS-ID feasibility study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: helicobacter pylori - diagnosis, optimal treatment and follow-up]
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2024     Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C: a short report update
2024     NIHR Health and Social Care Delivery Program The use of locum doctors in the NHS: understanding and improving the quality and safety of care
2024     NIHR Health Technology Assessment programme Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clozapine blood level testing by immunoassay]
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024     NIHR Health Services and Delivery Research programme Patient buy-in to social prescribing through link workers as part of person-centred care: a realist evaluation
2024     NIHR Health Technology Assessment programme Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood determination of a panel of anti-tuberculosis drugs using a multiplex approach by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in the context of clinical pharmacometrics]
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, gating mutation, heterozygous) – Benefit assessment according to §35a]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: overview of mobile applications in health and social services]
2024     NIHR Health Technology Assessment programme Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (Dravet syndrome) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal). NICE technology appraisal guidance 965
2024     NIHR Health Technology Assessment programme Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews
2024     NIHR Health and Social Care Delivery Program Implementing an artificial intelligence command centre in the NHS: a mixed-methods study
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (tuberous sclerosis) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 964
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and White British people presenting to emergency services for injury: the stakeholder consultation
2024     NIHR Health and Social Care Delivery Program Using the Recommended Summary Plan for Emergency Care and Treatment in Primary Care: a mixed methods study
2024     Agency for Care Effectiveness (ACE) KidneyIntelX for patients with diabetic kidney disease
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2024     Penn Medicine Center for Evidence-based Practice (CEP) Hyperbaric oxygen therapy for injury recovery among athletes
2024     NIHR Health Services and Delivery Research programme Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     Agency for Care Effectiveness (ACE) Oxevision for vision-based patient monitoring and management in mental health wards
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     NIHR Health and Social Care Delivery Program What happens between first symptoms and first acute exacerbation of COPD – observational study of routine data and patient survey
2024     Agency for Care Effectiveness (ACE) FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health and Social Care Delivery Program Pathways to specialist community perinatal mental health services: a two-site longitudinal retrospective service evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, other/unknown mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024     NIHR Health Technology Assessment programme Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2024     Norwegian Institute of Public Health (NIPH) [Robot–assisted hysterectomy for benign conditions: A rapid health technology assessment]
2024     Institute for Clinical and Economic Review (ICER) Sotatercept for pulmonary arterial hypertension
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood quantification of fludarabine by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)]
2024     Institute for Clinical and Economic Review (ICER) KarXT for schizophrenia